Annette von Delft
M.D, Ph.D.
Translational Scientist
Annette trained as a medical doctor at University of Leipzig (Germany) and received her D.Phil in Clinical Medicine at the University of Oxford in 2010. Her project focused on HCV T cell immunology and vaccine development under the supervision of Prof Eleanor Barnes. She then completed her medical foundation programme at Oxford University Hospitals.
Annette joined the BRC team in 2018 as a translational scientist with a focus on inflammation and immunity. She is currently involved in a range of projects in immunology, infectious disease and neuroscience.
Recent publications
-
Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors.
Journal article
Boby ML. et al, (2023), Science, 382
-
Accelerating antiviral drug discovery: lessons from COVID-19.
Journal article
von Delft A. et al, (2023), Nat Rev Drug Discov
-
Incoming HIV virion-derived Gag Spacer Peptide 2 (p1) is a target of effective CD8+ T cell antiviral responses.
Journal article
Yang H. et al, (2021), Cell Rep, 35
-
Open Science Discovery of Potent Non-Covalent SARS-CoV-2 Main Protease Inhibitors
Journal article
Boby ML. et al, (2020)
-
Viral vectored hepatitis C virus vaccines generate pan-genotypic T cell responses to conserved subdominant epitopes.
Journal article
Donnison T. et al, (2020), Vaccine, 38, 5036 - 5048